Participated · Series B · May 2023

Cadence Neuroscience develops a neuromodulation therapy that uses chronic subthreshold cortical stimulation to modulate EEG biomarkers and reduce or eliminate seizures. The therapy is based on research from a Mayo Clinic neurology and neurosurgery team led by Gregory Worrell, M.D., Ph.D. Cadence is clinical‑stage and intends to use the new funding to complete pivotal clinical studies and pursue FDA clearance. The company is led by CEO Kent Leyde and was founded in 2017. It is based in Redmond, WA and focuses on treating both pediatric and adult patients with focal drug‑resistant epilepsy. Cadence recently closed a Series B financing to advance its clinical program. Cadence Neuroscience is an early-stage medical device company founded in 2017 by Kent Leyde and based in Redmond, Wash. Its core technology was developed at Mayo Clinic’s Rochester campus and is currently under clinical evaluation. The company is developing a therapy that uses chronic subthreshold cortical stimulation to modulate EEG biomarkers associated with epilepsy to reduce or eliminate seizures; the approach was developed by a Mayo Clinic neurology and neurosurgery team led by Gregory Worrell, Mathew Stead, Brian Lundstrom, Ben Brinkmann and Jamie VanGompel. Cadence plans to use new funding to further develop the technology, conduct clinical studies, and pursue FDA approval. The company focuses on therapies for epilepsy and other neurological disorders and remains in early clinical and development stages.

Participated · Series A · Mar 2020

ShiraTronics develops a Migraine Therapy System that delivers neurostimulation intended to reduce headache days and attack severity and improve quality of life for chronic migraine patients. The company reported encouraging reductions in headache days, decreased migraine severity, and improved quality-of-life scores in its first-in-human pilot study. ShiraTronics received Breakthrough Device designation from the FDA's CDRH in 2021. It is now running an FDA-approved pivotal trial (RELIEV-CM2), a multi-center, blinded, randomized, sham-controlled study targeting patients who have failed current medical therapies. The company plans to use new funding to support that pivotal trial, pursue FDA premarket approval, and fund the initial commercial launch of its therapy. Rob Binney serves as CEO and is leading the company through these regulatory and commercialization milestones. ShiraTronics is a Brooklyn Park, Minnesota-based private medical device company focused on an innovative therapy for migraine headaches. The company is developing and clinically testing a neuromodulation technology as its core product. ShiraTronics was spun off from NuXcel, an electrical medical device accelerator. The company is led by President and CEO Lynn Elliott and co-founder and Chairman Mudit K. Jain, PhD. It completed an additional $3M Series A, bringing the Series A to $36M, and intends to use the funds to further accelerate its path to market. ShiraTronics is a Minneapolis-based private medical device company developing an innovative neuromodulation approach to treat migraine headaches. The company is focused on developing and clinically testing its neuromodulation technology. ShiraTronics was seeded in 2019 as a spin-off from NuXcel, a medical device accelerator managed by co-founder Mudit K. Jain, PhD, and Lynn Elliott. Lynn Elliott joined as President and CEO, with Mudit K. Jain serving as co-founder and Chairman of the Board. Prior to the Series A the company was backed by Strategic HealthCare Investment Partners (S.H.I.P.). In October 2019 ShiraTronics completed a $33M Series A financing to advance its clinical development.

Participated · Series B · Sep 2018

Ceribell deploys a cloud‑linked, portable electroencephalogram (EEG) device—the Ceribell Rapid Response EEG System—that can be applied quickly by any healthcare provider to assess brain waves in minutes and identify seizures and other conditions in emergency departments and intensive care units. The system delivers brain monitoring results within minutes and was first cleared by the FDA via 510(k) in 2017; it is commercially available in the United States. Ceribell is focused on making EEG widely available, more efficient, and more cost‑effective to improve diagnosis and treatment of neurological conditions for at‑risk patients. The company plans to leverage machine learning and easy EEG accessibility to address additional neurological indications beyond seizures and recently received Breakthrough Device Designation from the FDA for a delirium indication. Ceribell closed a $50 million equity financing to support ongoing commercial expansion across EDs and ICUs and to further develop its technology. The company is headquartered in Sunnyvale, California. Ceribell develops an FDA-cleared, point-of-care EEG system that uses real-time cloud computing and the proprietary Clarity™ machine learning algorithm to deliver rapid bedside seizure diagnosis. Its Ceribell EEG System received FDA 510(k) clearance in 2017 and is commercially available in the United States. The company is led by CEO and co-founder Jane Chao. Ceribell’s platform targets faster diagnosis in patients with suspected seizures, focusing on emergency departments and intensive care units. The company plans to use the new funding to further expand its commercial presence in EDs and ICUs globally. No revenue or user metrics were provided in the article. Ceribell develops a Rapid Response EEG System that uses a disposable headband and a mobile recorder to acquire and transmit EEG data to a HIPAA-compliant cloud portal for remote specialist review. The system is designed for bedside triage and can be set up in minutes by any healthcare provider, using a proprietary "Brain Stethoscope" feature that converts EEG signals to sound. Ceribell's EEG System received FDA 510(k) clearance in 2017 and is commercially available in the United States. The company is led by CEO Jane Chao, Ph.D. Ceribell plans to use the proceeds from its recent financing to expand commercialization of its system.

Participated · Equity · Oct 2017

HighLife develops a transcatheter mitral valve replacement (TMVR) system for patients with mitral regurgitation. The company's technology is designed for transseptal delivery via the femoral vein, is reversible, and self-locates inside the native annulus. Founded in 2010 by Georg Börtlein, HighLife is based in Paris and also has offices in Irvine, California. The company closed a €32m Series B equity financing round co‑led by U.S. Venture Partners and Andera Partners, with participation from Sofinnova Partners, Sectoral Asset Management and Jose Calle Gordo. It intends to use the funds to complete development of its transcatheter transseptal mitral valve implantation program, including regulatory approval trials in Europe to obtain a CE mark and a first clinical trial in the U.S. via an Early Feasibility Study (EFS). The financing supports advancement toward those clinical and regulatory milestones. HighLife is developing a unique trans-catheter mitral valve replacement (TMVR) system that treats mitral regurgitation using a two-step ring-and-bioprosthesis approach. The technology uses an initially placed reversible ring around the native mitral leaflets; once position is confirmed, a bioprosthesis is delivered within minutes through the ring to seat inside the native annulus. The delivery is designed for trans-septal access via the femoral vein and a puncture through the inter-atrial septum, avoiding a trans-apical puncture and reducing trauma by enabling a beating-heart procedure. HighLife is currently recruiting patients in several European countries, including France and Germany, and plans to accelerate enrollment of its initial clinical phase while advancing its R&D pipeline. Financially, the company has closed a €12.3 million investment round led by Sofinnova Partners, with participation from LivaNova PLC and founder Georg Börtlein. Founded in 2010 and headquartered in Paris with offices in Irvine, Calif., HighLife positions its TMVR technology for next-generation clinical adoption.